Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia

Fludarabine, cyclophosphamide, and rituximab (FCR) has represented a significant treatment advancement in chronic lymphocytic leukemia (CLL). In the new scenario of targeted agents, there is an increasing interest in identifying patients who gain the maximum benefit from FCR. In this observational m...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Rossi, Davide, Terzi-di-Bergamo, Lodovico, De Paoli, Lorenzo, Cerri, Michaela, Ghilardi, Guido, Chiarenza, Annalisa, Bulian, Pietro, Visco, Carlo, Mauro, Francesca R., Morabito, Fortunato, Cortelezzi, Agostino, Zaja, Francesco, Forconi, Francesco, Laurenti, Luca, Del Giudice, Ilaria, Gentile, Massimo, Vincelli, Iolanda, Motta, Marina, Coscia, Marta, Rigolin, Gian Matteo, Tedeschi, Alessandra, Neri, Antonino, Marasca, Roberto, Perbellini, Omar, Moreno, Carol, Del Poeta, Giovanni, Massaia, Massimo, Zinzani, Pier Luigi, Montillo, Marco, Cuneo, Antonio, Gattei, Valter, Foà, Robin, Gaidano, Gianluca
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2015
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4743433/
https://ncbi.nlm.nih.gov/pubmed/26276669
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-05-647925
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados